General
Preferred name
RITONAVIR
Synonyms
RTV ()
Abbott 84538 ()
A 84538 ()
ABT 538 ()
ABT-538,A 84538, RTV, Norvir, Norvir Softgel ()
Ritonavir (ABT-538) ()
Ritonavir ()
Ritonavir mylan ()
Viriton ()
A-84538 ()
Ritonavir component of paxlovid ()
Viekirax ()
Norvir ()
Ritovir ()
ABBOTT-84538 ()
Ritonavir related compounds mixture ()
Ritonavir component of xiannuoxin ()
Ritonavir component of kaletra ()
Empetus ()
Ritonavir component of technivie ()
Ritomune ()
Ritonavir component of viekirax ()
ABT-538 ()
NSC-693184 ()
Ritonavirum ()
Ritonavir-d6 ()
P&D ID
PD001134
CAS
155213-67-5
1217720-20-1
Tags
available
drug
Approved by
EMA
PMDA
FDA
First approval
1996
Drug indication
chronic hepatitis C virus infection
Human immunodeficiency virus infection
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCPRITION
Ritonavir is a peptidomimetic inhibitor of the HIV-1 protease. Inhibition of HIV protease renders the enzyme incapable of processing the Gag-Pol polyprotein precursor which leads to production of non-infectious immature HIV particles.
DESCRIPTION
Ritonavir is an orally bioavailable antiviral that is generally administered in combination with other anti-HIV or anti-HCV drugs.
(GtoPdb)
DESCRIPTION
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 ¦ÌM.
PRICE
52
DESCRIPTION
Potent and selective DDR1 inhibitor; orally bioavailable
(Tocris Bioactive Compound Library)
DESCRIPTION
Ritonavir is an inhibitor of HIV protease and Cytochrome P450, used to treat HIV infection and AIDS.
(Enamine Bioactive Compounds)
DESCRIPTION
Ritonavir (ABT 538) is a peptidomimetic agent that inhibits both HIV-1 and HIV-2 proteases. Ritonavir is highly inhibited by serum proteins but boosts the effect of other HIV proteases by blocking their degradation by cytochrome P450.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
2
Organisms
11
Compound Sets
32
AdooQ Bioactive Compound Library
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMAP Approved Drugs
Enamine Bioactive Compounds
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
NCATS Inxight Approved Drugs
NIH Clinical Collections (NCC)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
The Spectrum Collection
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
55
Molecular Weight
720.31
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
4
Rotatable Bonds
17
Ring Count
4
Aromatic Ring Count
4
cLogP
5.91
TPSA
145.78
Fraction CSP3
0.43
Chiral centers
4.0
Largest ring
6.0
QED
0.11
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Apoptosis
HIV
HIV Protease
SARS-CoV
CYP1A2, CYP2B6, CYP2C19, CYP2C8, CYP2C9, CYP2D6, CYP2E1, CYP3A4, CYP3A5, CYP3A7
HIV protease inhibitor
Apoptosis related,COVID-19,HIV Protease,P450 (e.g. CYP17)
Primary Target
Other Proteases
MOA
Inhibitor
HIV Protease inhibitor
Indication
human immunodeficiency virus (HIV-1)
Therapeutic Class
Anti-HIV Agents
Pathway
Microbiology/virology
Proteases/Proteasome
Anti-infection
Metabolic Enzyme/Protease
Source data
